全文获取类型
收费全文 | 1037篇 |
免费 | 80篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 51篇 |
妇产科学 | 22篇 |
基础医学 | 90篇 |
口腔科学 | 45篇 |
临床医学 | 93篇 |
内科学 | 255篇 |
皮肤病学 | 17篇 |
神经病学 | 41篇 |
特种医学 | 109篇 |
外科学 | 133篇 |
综合类 | 42篇 |
预防医学 | 77篇 |
眼科学 | 26篇 |
药学 | 71篇 |
中国医学 | 1篇 |
肿瘤学 | 57篇 |
出版年
2023年 | 7篇 |
2022年 | 8篇 |
2021年 | 8篇 |
2020年 | 9篇 |
2019年 | 8篇 |
2018年 | 26篇 |
2017年 | 14篇 |
2016年 | 21篇 |
2015年 | 20篇 |
2014年 | 9篇 |
2013年 | 27篇 |
2012年 | 53篇 |
2011年 | 63篇 |
2010年 | 34篇 |
2009年 | 47篇 |
2008年 | 32篇 |
2007年 | 57篇 |
2006年 | 38篇 |
2005年 | 35篇 |
2004年 | 31篇 |
2003年 | 43篇 |
2002年 | 34篇 |
2001年 | 24篇 |
2000年 | 24篇 |
1999年 | 21篇 |
1998年 | 23篇 |
1997年 | 41篇 |
1996年 | 35篇 |
1995年 | 21篇 |
1994年 | 22篇 |
1993年 | 24篇 |
1992年 | 8篇 |
1991年 | 35篇 |
1990年 | 22篇 |
1989年 | 19篇 |
1988年 | 22篇 |
1987年 | 17篇 |
1986年 | 16篇 |
1985年 | 23篇 |
1984年 | 12篇 |
1983年 | 14篇 |
1982年 | 10篇 |
1981年 | 16篇 |
1980年 | 13篇 |
1979年 | 4篇 |
1978年 | 9篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1974年 | 5篇 |
1973年 | 5篇 |
排序方式: 共有1137条查询结果,搜索用时 15 毫秒
71.
72.
American Academy of Pediatrics Committee on Early Childhood Adoption Dependent Care 《Pediatrics》2005,115(1):187-191
High-quality early education and child care for young children improves their health and promotes their development and learning. Early education includes all of a child's experiences at home, in child care, and in other preschool settings. Pediatricians have a role in promoting access to quality early education and child care beginning at birth for all children. The American Academy of Pediatrics affords pediatricians the opportunity to promote the educational and socioemotional needs of young children with other advocacy groups. 相似文献
73.
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial 总被引:4,自引:0,他引:4
Schooler N Rabinowitz J Davidson M Emsley R Harvey PD Kopala L McGorry PD Van Hove I Eerdekens M Swyzen W De Smedt G;Early Psychosis Global Working Group 《The American journal of psychiatry》2005,162(5):947-953
OBJECTIVE: The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment cornerstone during the first years of illness because active psychotic illness may affect lifetime outcomes. Thus, initial treatment of active symptoms and subsequent relapse prevention are central goals of pharmacotherapy. This study compared long-term effectiveness of risperidone versus haloperidol in first-episode psychosis patients. METHOD: First-episode psychosis patients (N=555, mean age=25.4 years) participated in a double-blind, randomized, controlled flexible-dose trial that compared risperidone (mean modal dose=3.3 mg) and haloperidol (mean modal dose=2.9 mg). The median treatment length was 206 days (maximum=1,514). RESULTS: Positive and Negative Syndrome Scale scores and Clinical Global Impression ratings improved significantly relative to baseline, with no significant differences between groups. Three-quarters of the patients achieved initial clinical improvement, defined as >20% reduction in total Positive and Negative Syndrome Scale score. However, among those who achieved clinical improvement, 42% of the risperidone group experienced a relapse compared with 55% of the haloperidol group. The median time to relapse was 466 days for risperidone-treated subjects and 205 days for those given haloperidol. These differences were statistically significant based on Kaplan-Meier survival analysis. Adverse effects distinguished the treatments: there were significantly more extrapyramidal signs and symptoms and adjunctive medication use in the haloperidol group and greater prolactin elevation in the risperidone group. There was less weight gain with haloperidol initially but no significant differences between groups at endpoint. CONCLUSIONS: Relatively low doses of antipsychotic drugs lead to significant symptom amelioration in the majority of first-episode psychosis patients. In the long term, risperidone prevents relapse in more patients and for a longer time and also induces less abnormal movements than haloperidol. 相似文献
74.
Neurobehavioral performance in preschool children from agricultural and non-agricultural communities in Oregon and North Carolina 总被引:2,自引:0,他引:2
Rohlman DS Arcury TA Quandt SA Lasarev M Rothlein J Travers R Tamulinas A Scherer J Early J Marín A Phillips J McCauley L 《Neurotoxicology》2005,26(4):589-598
Organophosphate (OP) pesticides produce acute toxic effects but little is known about low-level chronic exposures. Latino children of agricultural workers have a high risk of exposure to pesticides because of the close proximity of their homes to fields where pesticides are applied and from take-home exposure. Neurobehavioral performance of preschool children from agricultural (AG) communities was compared to performance of those from non-agricultural (Non-AG) communities in Oregon and North Carolina. Seventy-eight children aged 48-71 months completed a battery of neurobehavioral tests two times, approximately 1 month apart. Multiple regression revealed that the AG children performed poorer on measures of response speed (Finger Tapping) and latency (Match-to-Sample) compared to the Non-AG children. These results demonstrate modest differences in AG children compared to Non-AG children that are consistent with functional effects seen in adults exposed to low concentrations of OP pesticides. Just as was the case following early research on adults poisoned by pesticides, this study points to the need for additional investigations to test the hypothesis that low-concentration OP exposures affect acquisition of test performance, response speed and latency in children of agricultural workers. 相似文献
75.
76.
Guilbert TW Morgan WJ Krawiec M Lemanske RF Sorkness C Szefler SJ Larsen G Spahn JD Zeiger RS Heldt G Strunk RC Bacharier LB Bloomberg GR Chinchilli VM Boehmer SJ Mauger EA Mauger DT Taussig LM Martinez FD;Prevention of Early Asthma in Kids Study Childhood Asthma Research Education Network 《Controlled clinical trials》2004,25(3):286-310
Pediatric asthma remains an important public health concern as its prevalence and cost to the health care system is rising. In order to promote innovative research in asthma therapies, the National Heart, Lung and Blood Institute created the Childhood Asthma Research and Education Network in 1999. As its first study, the steering committee of the Childhood Asthma Research and Education Network designed a randomized clinical trial to determine if persistent asthma could be prevented in children at a high risk to develop the disease. This communication presents the design of its first clinical trial, the Prevention of Asthma in Kids (PEAK) trial and the organization of the Childhood Asthma Research and Education Network that developed and implemented this trial. Studies of the natural history of asthma have shown that, in persistent asthma, the initial asthma-like symptoms and loss of lung function occur predominately during the first years of life. Therefore, in the Prevention of Asthma in Kids study, children 2 and 3 years old with a positive asthma predictive index were randomized to twice daily treatment with fluticasone 88 microg or placebo via metered-dose inhaler and Aerochamber for 2 years. The double blind treatment period was followed by a 1-year observational period. Lung function was measured by spirometry and oscillometry technique at 4-month intervals throughout the study. Bronchodilator reversibility and exhaled nitric oxide (ENO) studies were performed at the end of the treatment and observation periods. The primary outcome measure was the number of asthma-free days. Other secondary outcomes included number of exacerbations, use of asthma medications and lung function. These measures were chosen to reflect the progression of the disease from intermittent wheezing to persistent asthma and measurement of the extent of airflow limitation and airway reactivity. 相似文献
77.
78.
Heijl A Leske MC Bengtsson B Bengtsson B Hussein M;Early Manifest Glaucoma Trial Group 《Acta ophthalmologica Scandinavica》2003,81(3):286-293
AIMS: The Early Manifest Glaucoma Trial (EMGT) (316 eligible eyes) has used a new set of criteria to define visual field progression in glaucoma. This paper provides estimates of the amount of visual field worsening required to reach the EMGT definition of definite perimetric progression. METHODS: In the 148 eyes that reached definite progression, we first determined changes between baseline and the time of definite EMGT progression, both for mean deviation (MD) and for number of highly (p < 0.5%) significantly depressed test points in pattern deviation probability maps. Second, we studied whether such changes depended on baseline MD, intraocular pressure (IOP), age and time to progression, all of which are factors that affect the rate of field progression. RESULTS: In eyes reaching progression, the mean change in MD from baseline was -1.93 dB (SE +/- 0.20) and the mean change in number of significant points was +4.85 (SE +/- 0.35). These changes did not show linear dependency on baseline MD, IOP or time to progression. CONCLUSIONS: The average amount of field deterioration needed to reach EMGT visual field progression has been measured and expressed in more conventional units (i.e. a loss of about - 2dB in MD and an increase in about five highly significant points). These estimates will facilitate the clinical interpretation of the results of EMGT. 相似文献
79.
Chollet P Schöffski P Weigang-Köhler K Schellens JH Cure H Pavlidis N Grünwald V De Boer R Wanders J Fumoleau P;EORTC Early Clinical Studies Group 《European journal of cancer (Oxford, England : 1990)》2003,39(9):1264-1270
S-1 is a new oral fluorinated pyrimidine derivate, in which the oral 5-fluorouracil (5-FU) prodrug, tegafur, was combined with two 5-FU-modulating substances, 5-chloro-2,4-dihydroxypyridine (gimeracil), and potassium oxonate (oteracil), at a molar ratio of 1:0.4:1. The final mechanism of action is exerted by 5-FU. The present study is the first European phase II trial of S-1 in gastric cancer. The primary study objectives were the safety, toxicity and activity of S-1 in non-pretreated patients with gastric cancer. The secondary objective was the duration of response. Patients had to have histologically- or cytologically-verified metastatic or locally advanced, unresectable gastric cancer; S-1 was administered orally twice daily at 40, then 35 mg/m(2) for 28 days every 5 weeks. The starting dose of 40 mg/m(2) was found to be intolerable due to significant non-haematological toxicity, and this dose was rapidly reduced to 35 mg/m(2) twice daily. Of the 7 patients enrolled at the 40 mg/m(2) level, only 3 were evaluable. At 35 mg/m(2), a response rate of 26.1% (95% Confidence Interval (CI) 12.0-45.1%) in 23 enrolled patients, and 31.6% (C.I. 14.7-53.0%) in 19 evaluable patients according to an independent radiology review, was found. The median duration of response at 35 mg/m(2) (6 patients) was 223 days (range, 108-828 days), and of stable disease was 111 days (range 68-411 days). S-1 can be administered with an acceptable safety and toxicity in European patients at a dose of 35 mg/m(2) days 1 - 28 every 5 weeks and is associated with a moderate response rate similar to the results achieved with other fluoropyrimidines. 相似文献
80.
Tredwell SJ Wilson D Wilmink MA;Canadian Early Mid-Trimester Amniocentesis Trial Group 《Journal of pediatric orthopedics》2001,21(5):636-641
A recent publication by the Canadian Early and Mid-Trimester Amniocentesis Trial Group reported an increase in orthopaedic foot deformities in infants whose mothers underwent an amniocentesis from 11 to 12 + 6 gestational weeks versus a group sampled between 15 to 16 + 6 gestational weeks. Because the sampling of the former group was at the time of maximum foot growth and maximum acquisition of amniotic fluid, the authors hypothesize that the foot deformities are secondary to decreased fetal movement during a key phase in foot and ankle development. 相似文献